FIRDAPSE

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug FIRDAPSE contains one active pharmaceutical ingredient (API):

1	Amifampridine UNII 8HF8FIN815 - AMIFAMPRIDINE PHOSPHATE
	Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarisation. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intra-cellular calcium concentrations facilitates exocytosis of acetylcholine-containing vesicles, which in turn enhances neuromuscular transmission.
	Read more about Amifampridine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FIRDAPSE Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
FIRDAPSE Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07XX05	Amifampridine	N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02502984
EE	Ravimiamet	1455465
FI	Lääkealan turvallisuus- ja kehittämiskeskus	113885
FR	Base de données publique des médicaments	69935992
GB	Medicines & Healthcare Products Regulatory Agency	180363
IL	מִשְׂרַד הַבְּרִיאוּת	6711
LT	Valstybinė vaistų kontrolės tarnyba	1052910
NL	Z-Index G-Standaard, PRK	96474
PL	Rejestru Produktów Leczniczych	100309728
US	FDA, National Drug Code	69616-211